Gugliotta G, Castagnetti F, Breccia M, Levato L, D’Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Rossi AR, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica [Internet]. 2015Sep.4 [cited 2026Nov.11];100(9):1146-50. Available from: https://haematologica.org/article/view/7489